
The Invesco Dorsey Wright Healthcare Momentum ETF (PTH) is structured to mirror the performance of the Dorsey Wright Healthcare Technical Leaders Index. This exchange-traded fund typically allocates a minimum of 90% of its total assets to the equities found within this benchmark index. The Index itself is specifically engineered to identify healthcare companies that demonstrate strong "relative strength," which indicates significant momentum. It consists of no fewer than 30 individual securities selected from the broader NASDAQ US Benchmark Index. "Relative strength" refers to the process of…
Is PTH's expense ratio expensive, average, or a steal for its category?
Pro reveals the verdict on a 5-tier spectrum calibrated against ICI 2025 industry averages, with strategy-aware bands so the comparison is meaningful.

HONG KONG, Aug 31, 2026 - (ACN Newswire) - Operating Cash Flow Turns Positive for the First Time, with a Significantly Strengthened Capital StructureOn August 2

TEL AVIV, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that post-hoc data from its Phase 2 clinical trial of EB613 (oral PTH(1-34) tablet) has been selected for two presentations including the Plenary Poster Presentation at the American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meeting, taking place October 9–12, 2026, at the John B. Hynes Veterans Memorial Convention Center in Boston, Massachusetts. Plenary Posters are highly ranked poster presentations selected by the ASBMR program committee to be presented at the Welcome Reception and Plenary Poster Session of the ASBMR 2026 Annual Meeting.

If you're interested in broad exposure to the Healthcare - Broad segment of the equity market, look no further than the Invesco Dorsey Wright Healthcare Momentum ETF (PTH), a passively managed exchange traded fund launched on October 12, 2006.

EB612, a first-in-class long-acting PTH(1-34) oral peptide for hypoparathyroidism, produced robust bioavailability and sustained increases in calcium across three preclinical models; IND is expected in late 2026

COPENHAGEN, Denmark, June 13, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced Week 182 data from its completed Phase 3 PaTHway Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) demonstrated sustained efficacy and safety in adults with hypoparathyroidism. Over the three-and-a-half-year duration of the trial, TransCon PTH replicated the systemic actions of endogenous PTH, with a balanced, beneficial impact on the main target organ systems – CNS, kidney, small intestine, and bone – as demonstrated by improved quality of life and normalized and stable urine calcium, serum calcium, serum phosphate, and bone mineral density. These benefits were sustained while enabling independence from conventional therapy with active vitamin D and calcium.